Top ▲
Gene and Protein Information | ||||||
class A G protein-coupled receptor | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 7 | 325 | 6q25.3 | MAS1 | MAS1 proto-oncogene, G protein-coupled receptor | 47,49,71 |
Mouse | 7 | 324 | 17 8.69 cM | Mas1 | MAS1 oncogene | 12 |
Rat | 7 | 324 | 1q11 | Mas1 | MAS1 proto-oncogene, G protein-coupled receptor | 30,70 |
Gene and Protein Information Comments | ||||||
Homologs of MAS1 are absent in model organisms like Zebra fish (D. rerio), Fruit fly (D. melanogaster) and C. elegans [19]. |
Previous and Unofficial Names | |
MAS | angiotensin 1-7 receptor [45] | MAS1 proto-oncogene, G protein-coupled receptor | MAS1 proto-oncogene |
Database Links | |
Specialist databases | |
GPCRdb | mas_human (Hs), mas_mouse (Mm), mas_rat (Rn) |
Other databases | |
Alphafold | P04201 (Hs), P30554 (Mm), P12526 (Rn) |
ChEMBL Target | CHEMBL3559701 (Hs) |
Ensembl Gene | ENSG00000130368 (Hs), ENSMUSG00000068037 (Mm), ENSRNOG00000014971 (Rn) |
Entrez Gene | 4142 (Hs), 17171 (Mm), 25153 (Rn) |
Human Protein Atlas | ENSG00000130368 (Hs) |
KEGG Gene | hsa:4142 (Hs), mmu:17171 (Mm), rno:25153 (Rn) |
OMIM | 165180 (Hs) |
Pharos | P04201 (Hs) |
RefSeq Nucleotide | NM_002377 (Hs), NM_008552 (Mm), NM_012757 (Rn) |
RefSeq Protein | NP_002368 (Hs), NP_032578 (Mm), NP_036889 (Rn) |
UniProtKB | P04201 (Hs), P30554 (Mm), P12526 (Rn) |
Wikipedia | MAS1 (Hs) |
Download all structure-activity data for this target as a CSV file
Agonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific agonist tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Agonist Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other agonists at this receptor include cyclised angiotensin (1-7) [31], angioprotectin [29], angiotensin III and angiotensin IV [24]. Jackson et al. reported that angiotensins I and II activated the MAS1 receptor [28]. However, Dong et al. did not detect responses in MAS1-expressing cells exposed to angiotensins I and II [16]. It was then reported that angiotensin-(1-7), which can be generated from angiotensin II by angiotensin-converting enzyme 2(ACE2) and functions as a vasodilator and antiproliferative agent, binds to Mas-transfected cells and elicits arachidonic acid release [54] and nitric oxide [50]. Angiotensin III and IV can also induce a significant but less pronounced arachidonic acid release [24]. Angiotensin-(1-7) was shown to not activate MAS in G protein coupled receptor functional assays measuring calcium, inositol-1-phosphate and cAMP [5,58,72]. There is very poor pharmacological data including radioligand binding studies that suggest a direct interaction between Ang(1-7) and MAS [25,54,66]. Alamandine, a novel component in renin-angiotensin system (RAS), is reported to act through MrgD, a member of Mas related gene family (Mrg) for which MAS is the founding member [34]. |
Antagonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific antagonist tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antagonist Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[D-Pro7]-angiotensin (1-7) is an antagonist of the mouse MAS1 receptor [53]. |
Immunopharmacology Comments |
Experimental evidence from animal studies suggest a role for MAS1 in the anti-inflammatory pathway mediated by angiotensin-(1-7) [15,17]. |
Immuno Process Associations | ||
|
||
|
Primary Transduction Mechanisms | |
Transducer | Effector/Response |
Gi/Go family Gq/G11 family |
Phospholipase C stimulation Other - See Comments |
Comments:
Transducer Gi is linked to the effector cAMP inhibition. MAS is reported to activate G protein constitutively [9,72]. However, no G protein activation by MAS is observed upon stimulation with angiotensin-(1-7) [5,58,72]. MAS is shown to function as a physiological antagonist of AT1R by altering AngII response in different tissues in mice [32,48,62]. Complex vascular effects of Ang(1-7) involving interactions of MAS with AT1R and AT2R are reported in the hearts of MAS knockout mice [10]. MAS upregulates AT1R by constitutive activation of Gαq/11 and subsequent PKC-dependent phosphorylation of AT1R [9]. Trafficking defective AT1R is rescued by co-expression with MAS in CHO and COS7 cells [51]. MAS transformation of cells is mediated by Rac-dependent signaling in NIH 3T3 cells [73]. Expression of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) diminished transforming activity of MAS in NIH 3T3 cells [6]. |
|
References: 72 |
Tissue Distribution | ||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
Tissue Distribution Comments | ||||||||
The expression of MAS1 was higher in decidual explants from women carrying a female foetus than from women carrying a male foetus [65]. MAS1 mRNAs were not detected in human placenta when examined by quantitative real-time PCR [45]. |
Expression Datasets | |
|
Physiological Functions | ||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
Physiological Functions Comments | ||||||||
The physiological role of MAS1 is directly evident in knockout mice studies (see Physiological Consequences of Altering Gene Expression section). The role of MAS1 in several physiological functions is derived indirectly from studies wherein [D-Ala7]-angiotensin(1-7)/A779 or AVE 0991 antagonized the physiological effects of angiotensin-(1-7). |
Physiological Consequences of Altering Gene Expression | ||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
Physiological Consequences of Altering Gene Expression Comments | ||||||||||
Early Mas1 knockout mice were in a mixed genetic background (129xC57BL/6) [63]. Later these mice were backcrossed to generate knockout mice with pure C57Bl/6 [68] and FVB/N [55] genetic backgrounds to study strain-specific effects of MAS deficiency. |
Phenotypes, Alleles and Disease Models | Mouse data from MGI | ||||||||||||||||||
|
Gene Expression and Pathophysiology Comments | |
A recurring translocation site in chromosome 6q that contains MAS1 has been found to be associated with human malignant melanoma [60]. |
General Comments |
MAS1 is a human cellular oncogene [71]. MAS1 is maternally imprinted in foetal mice [61], but not in adult mice [57] and humans [49]. MAS1 is not imprinted in mice [1,36]. Information on miRNAs predicted to target MAS1 3'UTR can be found at TargetScan [21,35]. In humans, the MAS1 receptor is located on chromosome locus 6q24-27, which is also a protooncogene [PMID 3708691]. MAS1 was initially thought to be the GPCR for AngII, but was not accepted on grounds of pharmacology and pattern of tissue expression [3,28,41]. In 2003, Santos et al., proposed that MAS1 is a functional receptor for Ang(1-7) based on the observations that binding sites and in vivo physiological responses to Ang (1-7) is absent in mice harbouring Mas1 deletion [54]. At present, pharmacological support for direct interaction between Ang(1-7) and MAS1 including radioligand binding and/or conventional G protein mediated second messenger generation is weak [5,58,72]. Similar to Ang(1-7), its analogs like A-779, cyclized derivative and non-peptide mimetics (AVE 0991) do not affect MAS1-mediated G protein signaling [31,66]. Conventional G protein signaling by MAS1 was reported upon stimulation with Neuropeptide FF [16] and in response to other peptide and non-peptide ligands, but not by Ang(1-7) [5,58,72]. MAS1 has also been reported to activate G protein signaling and the small GTPase Rac1 signaling constitutively. At cellular level, Ang(1-7) treatment of human messangial cells or MAS1 transfected CHO and COS cells was shown to cause concentration-dependent release of arachidonic acid (AA) by stimulating mitogen activated protein kinase p38. Deletion of Mas1 gene in mice suggest functional involvement of MAS1 in behavioral processes and in cardiovascular, renal and several metabolic physiologies [11,13,23,27,43,55,64] the MAS1-null mice have increased anxiety, altered heart rate and blood pressure variability. MAS1 knockout mice exhibited impairment in cardiac function associated with profibrotic changes in the expression of extracellular matrix proteins in the hearts. Renal dysfunction and fibrogenic changes in the kidneys were also reported in MAS1 deficient. MAS1 deficient mice were also shown to have increased abdominal fat mass, dyslipidemia, increased levels of insulin and leptin and altered response of adipocytes to insulin. MAS1 deficiency was shown to offer protection from salt induced hypertension and from ischemia/reperfusion injury in both kidney and heart. Endothelial dysfunction resulting in imbalances in nitric oxide (NO) and reactive oxygen species was reported to be a common mechanism behind the MAS1 deficient mice exhibiting alterations in blood pressure and heart rate, and an increase in vascular resistance and decrease in blood flow in the kidney, lung, adrenal gland, mesentry, spleen and brown fat tissues. MAS1 and AT1R may heterooligomerize and result in the altered function and trafficking of AT1R [32,51,62]. Thus, MAS1 may interact with the components of the renin angiotensin receptor implying a role for MAS1 in physiology. The interaction between Ang(1-7) and MAS1 is perhaps indirect and complex, may involve cross-talk between different proteins or differential expression of genes. However, it is too early to qualify MAS1 as a member of the angiotensin receptor family. |
1. Alenina N, Bader M, Walther T. (2002) Imprinting of the murine MAS protooncogene is restricted to its antisense RNA. Biochem Biophys Res Commun, 290 (3): 1072-8. [PMID:11798184]
2. Alenina N, Baranova T, Smirnow E, Bader M, Lippoldt A, Patkin E, Walther T. (2002) Cell type-specific expression of the Mas proto-oncogene in testis. J Histochem Cytochem, 50 (5): 691-6. [PMID:11967280]
3. Ambroz C, Clark AJ, Catt KJ. (1991) The mas oncogene enhances angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors. Biochim Biophys Acta, 1133 (1): 107-11. [PMID:1721543]
4. Arumugam S, Thandavarayan RA, Palaniyandi SS, Giridharan VV, Arozal W, Sari FR, Soetikno V, Harima M, Suzuki K, Kodama M et al.. (2012) Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis. Toxicology, 291 (1-3): 139-45. [PMID:22120037]
5. Bikkavilli RK, Tsang SY, Tang WM, Sun JX, Ngai SM, Lee SS, Ko WH, Wise H, Cheung WT. (2006) Identification and characterization of surrogate peptide ligand for orphan G protein-coupled receptor mas using phage-displayed peptide library. Biochem Pharmacol, 71 (3): 319-37. [PMID:16336942]
6. Booden MA, Siderovski DP, Der CJ. (2002) Leukemia-associated Rho guanine nucleotide exchange factor promotes G alpha q-coupled activation of RhoA. Mol Cell Biol, 22 (12): 4053-61. [PMID:12024019]
7. Botelho-Santos GA, Bader M, Alenina N, Santos RA. (2012) Altered regional blood flow distribution in Mas-deficient mice. Ther Adv Cardiovasc Dis, 6 (5): 201-11. [PMID:23045193]
8. Bunnemann B, Fuxe K, Metzger R, Mullins J, Jackson TR, Hanley MR, Ganten D. (1990) Autoradiographic localization of mas proto-oncogene mRNA in adult rat brain using in situ hybridization. Neurosci Lett, 114 (2): 147-53. [PMID:2203997]
9. Canals M, Jenkins L, Kellett E, Milligan G. (2006) Up-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of Gq/G11 by MAS. J Biol Chem, 281 (24): 16757-67. [PMID:16611642]
10. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. (2005) Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension, 46 (4): 937-42. [PMID:16157793]
11. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. (2006) Effects of genetic deletion of angiotensin-(1-7) receptor Mas on cardiac function during ischemia/reperfusion in the isolated perfused mouse heart. Life Sci, 80 (3): 264-8. [PMID:17055538]
12. Cebra-Thomas JA, Tsai JY, Pilder SH, Copeland NG, Jenkins NA, Silver LM. (1992) Localization of the Mas proto-oncogene to a densely marked region of mouse chromosome 17 associated with genomic imprinting. Genomics, 13 (2): 444-6. [PMID:1612602]
13. Crouch E, Persson A, Chang D, Parghi D. (1991) Surfactant protein D. Increased accumulation in silica-induced pulmonary lipoproteinosis. Am J Pathol, 139 (4): 765-76. [PMID:1656758]
14. da Costa Gonçalves AC, Leite R, Fraga-Silva RA, Pinheiro SV, Reis AB, Reis FM, Touyz RM, Webb RC, Alenina N, Bader M et al.. (2007) Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. Am J Physiol Heart Circ Physiol, 293 (4): H2588-96. [PMID:17616753]
15. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, Bretas TL, Bader M, de Sousa LP, da Silva TA et al.. (2010) Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol, 185 (9): 5569-76. [PMID:20935211]
16. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. (2001) A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell, 106 (5): 619-32. [PMID:11551509]
17. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. (2012) Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways. Br J Pharmacol, 166 (6): 1964-76. [PMID:22339213]
18. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M et al.. (2009) Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS ONE, 4 (4): e5406. [PMID:19404405]
19. Fournier D, Luft FC, Bader M, Ganten D, Andrade-Navarro MA. (2012) Emergence and evolution of the renin-angiotensin-aldosterone system. J Mol Med, 90 (5): 495-508. [PMID:22527880]
20. Fraga-Silva RA, Pinheiro SV, Gonçalves AC, Alenina N, Bader M, Santos RA. (2008) The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med, 14 (1-2): 28-35. [PMID:18026570]
21. Friedman RC, Farh KK, Burge CB, Bartel DP. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19 (1): 92-105. [PMID:18955434]
22. Gaidarov I, Adams J, Frazer J, Anthony T, Chen X, Gatlin J, Semple G, Unett DJ. (2018) Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor. Cell Signal, 50: 9-24. [PMID:29928987]
23. Gava E, de Castro CH, Ferreira AJ, Colleta H, Melo MB, Alenina N, Bader M, Oliveira LA, Santos RA, Kitten GT. (2012) Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart. Regul Pept, 175 (1-3): 30-42. [PMID:22285513]
24. Gembardt F, Grajewski S, Vahl M, Schultheiss HP, Walther T. (2008) Angiotensin metabolites can stimulate receptors of the Mas-related genes family. Mol Cell Biochem, 319 (1-2): 115-23. [PMID:18636314]
25. Gironacci MM, Adamo HP, Corradi G, Santos RA, Ortiz P, Carretero OA. (2011) Angiotensin (1-7) induces MAS receptor internalization. Hypertension, 58 (2): 176-81. [PMID:21670420]
26. Guimarães GG, Santos SH, Oliveira ML, Pimenta-Velloso EP, Motta DF, Martins AS, Alenina N, Bader M, Santos RA, Campagnole-Santos MJ. (2012) Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. Peptides, 38 (1): 54-61. [PMID:22921883]
27. Heringer-Walther S, Gembardt F, Perschel FH, Katz N, Schultheiss HP, Walther T. (2012) The genetic deletion of Mas abolishes salt induced hypertension in mice. Eur J Pharmacol, 689 (1-3): 147-53. [PMID:22652430]
28. Jackson TR, Blair LA, Marshall J, Goedert M, Hanley MR. (1988) The mas oncogene encodes an angiotensin receptor. Nature, 335 (6189): 437-40. [PMID:3419518]
29. Jankowski V, Tölle M, Santos RA, Günthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO et al.. (2011) Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J, 25 (9): 2987-95. [PMID:21628446]
30. Johansson A, Helou K, Levan G. (1998) Cytogenetic localization of cancer-related genes in the rat and comparative mapping studies in human and mouse. Cytogenet Cell Genet, 81 (3-4): 217-21. [PMID:9730607]
31. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M. (2009) Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther, 328 (3): 849-54. [PMID:19038778]
32. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P et al.. (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation, 111 (14): 1806-13. [PMID:15809376]
33. Kumar M, Grammas P, Giacomelli F, Wiener J. (1996) Selective expression of c-mas proto-oncogene in rat cerebral endothelial cells. Neuroreport, 8 (1): 93-6. [PMID:9051759]
34. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A et al.. (2013) Discovery and characterization of alamandine: a novel component of the Renin-Angiotensin system. Circ Res, 112 (8): 1104-11. [PMID:23446738]
35. Lewis BP, Burge CB, Bartel DP. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120 (1): 15-20. [PMID:15652477]
36. Lyle R, Watanabe D, te Vruchte D, Lerchner W, Smrzka OW, Wutz A, Schageman J, Hahner L, Davies C, Barlow DP. (2000) The imprinted antisense RNA at the Igf2r locus overlaps but does not imprint Mas1. Nat Genet, 25 (1): 19-21. [PMID:10802648]
37. Mario EG, Santos SH, Ferreira AV, Bader M, Santos RA, Botion LM. (2012) Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes. Peptides, 33 (1): 174-7. [PMID:22119778]
38. Martin KA, Grant SG, Hockfield S. (1992) The mas proto-oncogene is developmentally regulated in the rat central nervous system. Brain Res Dev Brain Res, 68 (1): 75-82. [PMID:1521325]
39. Martin KA, Hockfield S. (1993) Expression of the mas proto-oncogene in the rat hippocampal formation is regulated by neuronal activity. Brain Res Mol Brain Res, 19 (4): 303-9. [PMID:8231733]
40. Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D. (1995) Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett, 357 (1): 27-32. [PMID:8001672]
41. Monnot C, Weber V, Stinnakre J, Bihoreau C, Teutsch B, Corvol P, Clauser E. (1991) Cloning and functional characterization of a novel mas-related gene, modulating intracellular angiotensin II actions. Mol Endocrinol, 5 (10): 1477-87. [PMID:1723144]
42. Peiró C, Vallejo S, Gembardt F, Azcutia V, Heringer-Walther S, Rodríguez-Mañas L, Schultheiss HP, Sánchez-Ferrer CF, Walther T. (2007) Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J Hypertens, 25 (12): 2421-5. [PMID:17984663]
43. Pinheiro SV, Ferreira AJ, Kitten GT, da Silveira KD, da Silva DA, Santos SH, Gava E, Castro CH, Magalhães JA, da Mota RK et al.. (2009) Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int, 75 (11): 1184-93. [PMID:19262461]
44. Pinheiro SV, Simões e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M et al.. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension, 44 (4): 490-6. [PMID:15326087]
45. Pringle KG, Tadros MA, Callister RJ, Lumbers ER. (2011) The expression and localization of the human placental prorenin/renin-angiotensin system throughout pregnancy: roles in trophoblast invasion and angiogenesis?. Placenta, 32 (12): 956-62. [PMID:22018415]
46. Rabelo LA, Xu P, Todiras M, Sampaio WO, Buttgereit J, Bader M, Santos RA, Alenina N. (2008) Ablation of angiotensin (1-7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction. J Am Soc Hypertens, 2 (6): 418-24. [PMID:20409925]
47. Rabin M, Birnbaum D, Young D, Birchmeier C, Wigler M, Ruddle FH. (1987) Human ros1 and mas1 oncogenes located in regions of chromosome 6 associated with tumor-specific rearrangements. Oncogene Res, 1 (2): 169-78. [PMID:3329713]
48. Rakušan D, Bürgelová M, Vaněčková I, Vaňourková Z, Husková Z, Skaroupková P, Mrázová I, Opočenský M, Kramer HJ, Netuka I et al.. (2010) Knockout of angiotensin 1-7 receptor Mas worsens the course of two-kidney, one-clip Goldblatt hypertension: roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II. Kidney Blood Press Res, 33 (6): 476-88. [PMID:21071955]
49. Riesewijk AM, Schepens MT, Mariman EM, Ropers HH, Kalscheuer VM. (1996) The MAS proto-oncogene is not imprinted in humans. Genomics, 35 (2): 380-2. [PMID:8661154]
50. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension, 49 (1): 185-92. [PMID:17116756]
51. Santos EL, Reis RI, Silva RG, Shimuta SI, Pecher C, Bascands JL, Schanstra JP, Oliveira L, Bader M, Paiva AC et al.. (2007) Functional rescue of a defective angiotensin II AT1 receptor mutant by the Mas protooncogene. Regul Pept, 141 (1-3): 159-67. [PMID:17320985]
52. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC et al.. (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension, 47 (5): 996-1002. [PMID:16567589]
53. Santos RA, Haibara AS, Campagnole-Santos MJ, Simões e Silva AC, Paula RD, Pinheiro SV, Leite MF, Lemos VS, Silva DM, Guerra MT et al.. (2003) Characterization of a new selective antagonist for angiotensin-(1-7), D-pro7-angiotensin-(1-7). Hypertension, 41 (3 Pt 2): 737-43. [PMID:12623989]
54. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M et al.. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA, 100 (14): 8258-63. [PMID:12829792]
55. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Pôrto LC, Alvarez-Leite JI, Botion LM, Bader M, Alenina N, Santos RA. (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes, 57 (2): 340-7. [PMID:18025412]
56. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y et al.. (2010) Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension, 56 (1): 112-20. [PMID:20479330]
57. Schweifer N, Valk PJ, Delwel R, Cox R, Francis F, Meier-Ewert S, Lehrach H, Barlow DP. (1997) Characterization of the C3 YAC contig from proximal mouse chromosome 17 and analysis of allelic expression of genes flanking the imprinted Igf2r gene. Genomics, 43 (3): 285-97. [PMID:9268631]
58. Shemesh R, Toporik A, Levine Z, Hecht I, Rotman G, Wool A, Dahary D, Gofer E, Kliger Y, Soffer MA et al.. (2008) Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J Biol Chem, 283 (50): 34643-9. [PMID:18854305]
59. Tallant EA, Ferrario CM, Gallagher PE. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol, 289 (4): H1560-6. [PMID:15951342]
60. Trent JM, Thompson FH, Meyskens FL. (1989) Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma. Cancer Res, 49 (2): 420-3. [PMID:2642739]
61. Villar AJ, Pedersen RA. (1994) Parental imprinting of the Mas protooncogene in mouse. Nat Genet, 8 (4): 373-9. [PMID:7894489]
62. Von Bohlen und Halbach O, Walther T, Bader M, Albrecht D. (2000) Interaction between Mas and the angiotensin AT1 receptor in the amygdala. J Neurophysiol, 83 (4): 2012-21. [PMID:10758111]
63. Walther T, Balschun D, Voigt JP, Fink H, Zuschratter W, Birchmeier C, Ganten D, Bader M. (1998) Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem, 273 (19): 11867-73. [PMID:9565612]
64. Walther T, Wessel N, Kang N, Sander A, Tschöpe C, Malberg H, Bader M, Voss A. (2000) Altered heart rate and blood pressure variability in mice lacking the Mas protooncogene. Braz J Med Biol Res, 33 (1): 1-9. [PMID:10625868]
65. Wang Y, Pringle KG, Sykes SD, Marques FZ, Morris BJ, Zakar T, Lumbers ER. (2012) Fetal sex affects expression of renin-angiotensin system components in term human decidua. Endocrinology, 153 (1): 462-8. [PMID:22045662]
66. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H. (2002) AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension, 40 (6): 847-52. [PMID:12468568]
67. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V et al.. (2008) Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension, 51 (2): 574-80. [PMID:18180400]
68. Xu P, Santos RA, Bader M, Alenina N. (2007) Alterations in gene expression in the testis of angiotensin-(1-7)-receptor Mas-deficient mice. Regul Pept, 138 (2-3): 51-5. [PMID:17196677]
69. Xu X, Quiambao AB, Roveri L, Pardue MT, Marx JL, Röhlich P, Peachey NS, Al-Ubaidi MR. (2000) Degeneration of cone photoreceptors induced by expression of the Mas1 protooncogene. Exp Neurol, 163 (1): 207-19. [PMID:10785460]
70. Young D, O'Neill K, Jessell T, Wigler M. (1988) Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. Proc Natl Acad Sci USA, 85 (14): 5339-42. [PMID:2455902]
71. Young D, Waitches G, Birchmeier C, Fasano O, Wigler M. (1986) Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell, 45 (5): 711-9. [PMID:3708691]
72. Zhang T, Li Z, Dang H, Chen R, Liaw C, Tran TA, Boatman PD, Connolly DT, Adams JW. (2012) Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol, 302 (1): H299-311. [PMID:22003054]
73. Zohn IE, Symons M, Chrzanowska-Wodnicka M, Westwick JK, Der CJ. (1998) Mas oncogene signaling and transformation require the small GTP-binding protein Rac. Mol Cell Biol, 18 (3): 1225-35. [PMID:9488437]